QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=9F5FCC6A1C39D797462965C98F3EAE55;jsessionid=B371A9006ED650EFEA76B2D2E42A0BC2;jsessionid=B9E6D7862725349126DB2BB3623F1BB1;jsessionid=97BED8DD7319878DAF109BC9A5A5B5D4;jsessionid=01A0DAA6DC08239A0959C0CD690BA63D (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
4. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
5. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=9F5FCC6A1C39D797462965C98F3EAE55;jsessionid=B371A9006ED650EFEA76B2D2E42A0BC2;jsessionid=B9E6D7862725349126DB2BB3623F1BB1;jsessionid=97BED8DD7319878DAF109BC9A5A5B5D4;jsessionid=01A0DAA6DC08239A0959C0CD690BA63D